| 35.71 Data as of Jun 18 | +0.30 / +0.85%Today’s Change | 18.48 Today|||52-Week Range 42.41 | +60.57% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $3.5B |
Theravance, Inc. 901 Gateway Boulevard South San Francisco California 94080 |

| Rick E. Winningham, MBA | Chairman & Chief Executive Officer |
| Michael W. Aguiar, MBA | CFO, Senior VP & Head-Investor Relations |
| Steve Barriere, PharmD | Vice President-Clinical & Medical Affairs |
| Daniel M. Canafax, PharmD | Vice President-Clinical Development |
| Oranee T. Daniels, MD | VP-Clinical Pharmacology & Experimental Medicine |